TriangleHEALTH PROFESSIONAL · SOURCE READING
Treatment Options for Stage III and Stage IV Oropharyngeal Cancer
Source: Oropharyngeal Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.
Source updated: May 14, 2025 · Captured 2026-09-09.
Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.
Context: Treatment of Stage III and Stage IV Oropharyngeal Cancer
Treatment options for stage III and stage IV oropharyngeal cancer include:
Surgery and postoperative radiation therapy (PORT) with or without chemotherapy for patients with advanced disease.[1-4][Level of evidence A1]
Radiation therapy using altered fractionation.[5-9][Level of evidence A1]
Source links and citations
Concurrent chemoradiation therapy.[10-15][Level of evidence A1]
Source links and citations
Neoadjuvant chemotherapy followed by concurrent chemoradiation therapy.
Source links and citations
Chemoradiation therapy with immunotherapy (under clinical evaluation). RTOG 3504 (NCT02764593) evaluated concurrent chemoradiation therapy with nivolumab in patients with intermediate- to high-risk head and neck cancer.
Source links and citations
Treatment de-intensification using radiation dose de-escalation is being studied in NRG-HN002 (NCT02254278).
Source links and citations
Treatment de-intensification using transoral surgery followed by radiation dose de-escalation is being studied in ECOG-3311 (NCT01898494).
Source links and citations
Studies cited in this source section
Source citation is not a determination that a study applies to you.
Publication references
Read the original reference and check its publication notices.
Preserved source evidence · Not medical advice